Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: Neurobiol Aging. 2018 Jun 11;70:70–77. doi: 10.1016/j.neurobiolaging.2018.06.004

Fig. 1.

Fig. 1.

Immunostaining for CD31 in the gray and white matter of AD subjects with CAA type 1, AD subjects with CAA type 2, AD subjects without CAA, and nondemented elderly subjects demonstrates (A) decreased staining for CD31 in the gray matter of AD subjects with CAA type 2 and (not shown) AD subjects with CAA type 1 compared with (B) AD subjects without CAA. This decrease is also seen in the white matter for AD patients with CAA type 2 compared with AD patients without CAA. (C) CD31 staining as mean ± SD. * p < 0.05, ** p < 0.01. Abbreviations: AD, Alzheimer disease; CAA, cerebral amyloid angiopathy; GM, gray matter; WM, white matter.

HHS Vulnerability Disclosure